Skip to main content
Erschienen in: Osteoporosis International 8/2014

01.08.2014 | Review

A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions

verfasst von: L. Si, T. M. Winzenberg, B. de Graaff, A. J. Palmer

Erschienen in: Osteoporosis International | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to statistically combine multiple health state utility values (HSUVs) reported in the literature for patients with osteoporosis and osteoporotic fractures. Fracture events were associated with decrements in HSUVs which differed between fracture sites. We have provided summary values for use in future health economics analyses in osteoporosis. Osteoporotic fractures have high financial and health burden. Economic evaluations on osteoporotic fracture prevention have been frequently performed in past decades. One of the challenges in the economic evaluations was to identify consistent health state utility values (HSUVs) to use for osteoporotic fracture-related conditions. The objective of this study was to determine summary measures of multiple HSUVs reported in the literature for patients with osteoporosis and osteoporotic fractures. We performed a systematic review, meta-analysis and meta-regression of published literature that reported HSUVs for osteoporotic fracture-related conditions. There were 62 studies representing 142,477 patients included. In total, 362 HSUVs were identified: 106 for pre-fracture; 89 for post-hip fracture; 130 for post-vertebral fracture and 37 for post-wrist fracture. The pooled HSUVs, using a random-effects model were 0.76 (95 % CI 0.75, 0.77, I 2 = 0.99) for pre-fracture; 0.57 (95 % CI 0.52, 0.63, I 2 = 1) for post-hip fracture; 0.59 (95 % CI 0.55, 0.62, I 2 = 0.99) for post-vertebral facture and 0.72 (95 % CI 0.67, 0.78, I 2 = 1) for post-wrist fracture. Heterogeneities were addressed through meta-regression. HSUVs immediately following hip, vertebral and wrist fractures were 0.31, 0.44 and 0.61, respectively. Patients’ HSUVs improved over time following fracture events: HSUVs for the first year after hip, vertebral and wrist fractures were 0.59, 0.55 and 0.78, respectively; and 0.66, 0.66 and 0.81 for subsequent years. Fractures were associated with significant decrements in HSUVs. This study provides a standard set of HSUVs that can be used in health economic assessments in osteoporosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kanis JA, Gluer CC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 11:192–202PubMedCrossRef Kanis JA, Gluer CC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 11:192–202PubMedCrossRef
2.
Zurück zum Zitat Kanis J (2007) WHO technical report. University of Sheffield, UK Kanis J (2007) WHO technical report. University of Sheffield, UK
3.
Zurück zum Zitat AIHW (2011) A snapshot of osteoporosis in Australia 2011. AIHW, Canberra AIHW (2011) A snapshot of osteoporosis in Australia 2011. AIHW, Canberra
4.
Zurück zum Zitat Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos 8:1–115CrossRef Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos 8:1–115CrossRef
5.
Zurück zum Zitat Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax(registered trademark)) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314PubMedCrossRef Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax(registered trademark)) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314PubMedCrossRef
6.
Zurück zum Zitat Tosteson ANA, Melton LJ III, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447PubMedCentralPubMedCrossRef Tosteson ANA, Melton LJ III, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495–505PubMedCrossRef Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495–505PubMedCrossRef
8.
Zurück zum Zitat Si L, Winzenberg TM, Palmer AJ (2014) A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int 25:51–60PubMedCrossRef Si L, Winzenberg TM, Palmer AJ (2014) A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int 25:51–60PubMedCrossRef
9.
Zurück zum Zitat Tosteson ANA, Jönsson B, Grima DT, O’Brien BJ, Black DM, Adachi JD (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12:849–857PubMedCrossRef Tosteson ANA, Jönsson B, Grima DT, O’Brien BJ, Black DM, Adachi JD (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12:849–857PubMedCrossRef
10.
Zurück zum Zitat Gabriel SE, Kneeland TS, Melton LJ 3rd, Moncur MM, Ettinger B, Tosteson AN (1999) Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Mak 19:141–148CrossRef Gabriel SE, Kneeland TS, Melton LJ 3rd, Moncur MM, Ettinger B, Tosteson AN (1999) Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Mak 19:141–148CrossRef
11.
Zurück zum Zitat Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G (2005) Methods for the economic evaluation of health care programmes. Oxford University Press, USA Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G (2005) Methods for the economic evaluation of health care programmes. Oxford University Press, USA
12.
Zurück zum Zitat Kaplan RM, Sieber WJ, Ganiats TG (1997) The quality of well-being scale: comparison of the interviewer-administered version with a self-administered questionnaire. Psychol Health 12:783–791CrossRef Kaplan RM, Sieber WJ, Ganiats TG (1997) The quality of well-being scale: comparison of the interviewer-administered version with a self-administered questionnaire. Psychol Health 12:783–791CrossRef
13.
Zurück zum Zitat Feeny D, Furlong W, Boyle M, Torrance GW (1995) Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics 7:490–502PubMedCrossRef Feeny D, Furlong W, Boyle M, Torrance GW (1995) Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics 7:490–502PubMedCrossRef
14.
Zurück zum Zitat Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21:271–292PubMedCrossRef Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21:271–292PubMedCrossRef
15.
Zurück zum Zitat Roberts J, Dolan P (2004) To what extent do people prefer health states with higher values? A note on evidence from the EQ-5D valuation set. Health Econ 13:733–737PubMedCrossRef Roberts J, Dolan P (2004) To what extent do people prefer health states with higher values? A note on evidence from the EQ-5D valuation set. Health Econ 13:733–737PubMedCrossRef
16.
Zurück zum Zitat Peasgood T, Herrmann K, Kanis JA, Brazier JE (2009) An updated systematic review of health state utility values for osteoporosis related conditions. Osteoporos Int 20:853–868PubMedCrossRef Peasgood T, Herrmann K, Kanis JA, Brazier JE (2009) An updated systematic review of health state utility values for osteoporosis related conditions. Osteoporos Int 20:853–868PubMedCrossRef
17.
Zurück zum Zitat Nakamura T, Osawa M, Itoh M, Yamaguchi H, Iinuma N, Hayakawa Y, Suzuki H, Kamisaki T, Iwayama S, Nishikawa M (2012) The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study. J Bone Miner Metab 30:715–721PubMedCrossRef Nakamura T, Osawa M, Itoh M, Yamaguchi H, Iinuma N, Hayakawa Y, Suzuki H, Kamisaki T, Iwayama S, Nishikawa M (2012) The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study. J Bone Miner Metab 30:715–721PubMedCrossRef
18.
Zurück zum Zitat Borgstrom F, Lekander I, Ivergard M et al (2013) The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)—quality of life during the first 4 months after fracture. Osteoporos Int 24:811–823PubMedCrossRef Borgstrom F, Lekander I, Ivergard M et al (2013) The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)—quality of life during the first 4 months after fracture. Osteoporos Int 24:811–823PubMedCrossRef
19.
Zurück zum Zitat Brazier J, Roberts J, Tsuchiya A, Busschbach J (2004) A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 13:873–884PubMedCrossRef Brazier J, Roberts J, Tsuchiya A, Busschbach J (2004) A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 13:873–884PubMedCrossRef
20.
Zurück zum Zitat Brazier JE, Green C, Kanis JA (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13:768–776PubMedCrossRef Brazier JE, Green C, Kanis JA (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13:768–776PubMedCrossRef
21.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, The Prisma Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097PubMedCentralPubMedCrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, The Prisma Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Brazier J, Papaioannou D, Cantrell A, Paisley S, Herrmann KH (2010) Chapter 8: Identifying and reviewing health state utility values for populatiing decision models. Evidence-based decisions and economics: health care, social welfare, education and criminal justice. Wiley-Blackwell, Oxford Brazier J, Papaioannou D, Cantrell A, Paisley S, Herrmann KH (2010) Chapter 8: Identifying and reviewing health state utility values for populatiing decision models. Evidence-based decisions and economics: health care, social welfare, education and criminal justice. Wiley-Blackwell, Oxford
23.
Zurück zum Zitat Berlin JA (1997) Does blinding of readers affect the results of meta-analyses? Lancet 350:185–186PubMedCrossRef Berlin JA (1997) Does blinding of readers affect the results of meta-analyses? Lancet 350:185–186PubMedCrossRef
24.
Zurück zum Zitat Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef
25.
Zurück zum Zitat Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clin Res Ed) 327:557–560CrossRef Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clin Res Ed) 327:557–560CrossRef
26.
Zurück zum Zitat Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration
27.
Zurück zum Zitat Higgins JPT, Thompson SG, Spiegelhalter DJ (2009) A re-evaluation of random-effects meta-analysis. J R Stat Soc: Ser A (Stat Soc) 172:137–159CrossRef Higgins JPT, Thompson SG, Spiegelhalter DJ (2009) A re-evaluation of random-effects meta-analysis. J R Stat Soc: Ser A (Stat Soc) 172:137–159CrossRef
28.
Zurück zum Zitat Altman DG, Bland JM (2005) Standard deviations and standard errors. BMJ (Clin Res Ed) 331:903CrossRef Altman DG, Bland JM (2005) Standard deviations and standard errors. BMJ (Clin Res Ed) 331:903CrossRef
29.
Zurück zum Zitat He Y (2010) Missing data analysis using multiple imputation: getting to the heart of the matter. Circ Cardiovas Qual Outcome 3:98–105CrossRef He Y (2010) Missing data analysis using multiple imputation: getting to the heart of the matter. Circ Cardiovas Qual Outcome 3:98–105CrossRef
30.
Zurück zum Zitat White IR, Royston P, Wood AM (2011) Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 30:377–399PubMedCrossRef White IR, Royston P, Wood AM (2011) Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 30:377–399PubMedCrossRef
31.
Zurück zum Zitat Harbord RM, Higgins JPT (2008) Meta-regression in Stata. Stata J 8:493–519 Harbord RM, Higgins JPT (2008) Meta-regression in Stata. Stata J 8:493–519
32.
Zurück zum Zitat Baum CF (2006) An introduction to modern econometrics using Stata. Stata Press Baum CF (2006) An introduction to modern econometrics using Stata. Stata Press
33.
Zurück zum Zitat Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559–1573PubMedCrossRef Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559–1573PubMedCrossRef
34.
Zurück zum Zitat Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ (1985) Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Dec Making : An Int J Soc Med Dec Making 5:157–177CrossRef Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ (1985) Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Dec Making : An Int J Soc Med Dec Making 5:157–177CrossRef
35.
Zurück zum Zitat Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ (Clin Res Ed) 316:736–741CrossRef Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ (Clin Res Ed) 316:736–741CrossRef
36.
Zurück zum Zitat Hiligsmann M, Reginster JY (2011) Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 29:895–911PubMedCrossRef Hiligsmann M, Reginster JY (2011) Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 29:895–911PubMedCrossRef
37.
Zurück zum Zitat NICE (2013) Guide to the methods of technology appraisal 2013. London NICE (2013) Guide to the methods of technology appraisal 2013. London
39.
Zurück zum Zitat Peasgood T, Ward S, Brazier J (2010) A review and meta-analysis of health state utility values in breast cancer. School of Health and Related Research. University of Sheffield, Sheffield Peasgood T, Ward S, Brazier J (2010) A review and meta-analysis of health state utility values in breast cancer. School of Health and Related Research. University of Sheffield, Sheffield
40.
Zurück zum Zitat Cockerill W, Lunt M, Silman AJ et al (2004) Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 15:113–119PubMedCrossRef Cockerill W, Lunt M, Silman AJ et al (2004) Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 15:113–119PubMedCrossRef
41.
Zurück zum Zitat Cherepanov D, Palta M, Fryback DG, Robert SA, Hays RD, Kaplan RM (2011) Gender differences in multiple underlying dimensions of health-related quality of life are associated with sociodemographic and socioeconomic status. Med Care 49:1021–1030PubMedCentralPubMedCrossRef Cherepanov D, Palta M, Fryback DG, Robert SA, Hays RD, Kaplan RM (2011) Gender differences in multiple underlying dimensions of health-related quality of life are associated with sociodemographic and socioeconomic status. Med Care 49:1021–1030PubMedCentralPubMedCrossRef
42.
Zurück zum Zitat Jakob F, Oertel H, Langdahl B et al (2012) Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol 166:87–97PubMedCentralPubMedCrossRef Jakob F, Oertel H, Langdahl B et al (2012) Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol 166:87–97PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Eidt-Koch D, Greiner W (2011) Quality of life results of balloon kyphoplasty versus non surgical management for osteoporotic vertebral fractures in Germany. Heal Econ Rev 1:7CrossRef Eidt-Koch D, Greiner W (2011) Quality of life results of balloon kyphoplasty versus non surgical management for osteoporotic vertebral fractures in Germany. Heal Econ Rev 1:7CrossRef
44.
Zurück zum Zitat Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20–26PubMedCrossRef Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20–26PubMedCrossRef
45.
Zurück zum Zitat Trikalinos TA, Olkin I (2012) Meta-analysis of effect sizes reported at multiple time points: a multivariate approach. Clin Trials 9:610–620PubMedCrossRef Trikalinos TA, Olkin I (2012) Meta-analysis of effect sizes reported at multiple time points: a multivariate approach. Clin Trials 9:610–620PubMedCrossRef
Metadaten
Titel
A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions
verfasst von
L. Si
T. M. Winzenberg
B. de Graaff
A. J. Palmer
Publikationsdatum
01.08.2014
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 8/2014
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-014-2636-2

Weitere Artikel der Ausgabe 8/2014

Osteoporosis International 8/2014 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.